| Description | SNT-207707 is a potent, selective and orally active antagonist of melanocortin MC-4 receptor(IC50 of 8 nM (binding) and 5 nM (function) on the MC-4 receptor). |
| In vitro | SNT-207707 binds to MC-4 receptor with an affinity of 8 nM, and has over 200-fold selectivity vs. MC-3 and MC-5. SNT207858 is a 22 nM MC-4 antagonist with a 170-fold selectivity vs. MC-3 and a 40-fold selectivity versus MC-5. |
| In vivo | food intake of the mice distinctly increased by SNT-207707(Single subcutaneous injection of 20 mg/kg). Once daily oral administration of both compounds SNT207858 and SNT-207707 starting the day after tumor implantation significantly reduces the tumor induced weight loss. |
| Target activity | MC-4 (binding):8 nM , MC-4 (function):5 nM |
| molecular weight | 550.18 |
| Molecular formula | C32H44ClN5O |
| CAS | 1064662-40-3 |
| Storage | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice. |
| Solubility | DMSO: 250 mg/mL (454.40 mM) MEthanol: 250 mg/mL (454.40 mM), Sonication is recommended. |
| References | 1. Weyermann P, et al. Orally available selective melanocortin-4 receptor antagonists stimulate food intake and reduce cancer-induced cachexia in mice. PLoS One. 2009;4(3):e4774. |